vs

Side-by-side financial comparison of Orange County Bancorp, Inc. (OBT) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $33.0M, roughly 1.1× Orange County Bancorp, Inc.). Orange County Bancorp, Inc. runs the higher net margin — 37.6% vs -304.2%, a 341.9% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 20.6%). Orange County Bancorp, Inc. produced more free cash flow last quarter ($41.3M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 14.3%).

Orange County Bancorp, Inc. is a Delaware-registered bank holding company operating mainly in New York, U.S. It offers a full range of retail and commercial banking services, including deposit accounts, loans and wealth management solutions, serving individual consumers, small and mid-sized corporate clients in its regional footprint.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

OBT vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.1× larger
RXRX
$35.5M
$33.0M
OBT
Growing faster (revenue YoY)
RXRX
RXRX
+661.1% gap
RXRX
681.7%
20.6%
OBT
Higher net margin
OBT
OBT
341.9% more per $
OBT
37.6%
-304.2%
RXRX
More free cash flow
OBT
OBT
$88.7M more FCF
OBT
$41.3M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
14.3%
OBT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OBT
OBT
RXRX
RXRX
Revenue
$33.0M
$35.5M
Net Profit
$12.4M
$-108.1M
Gross Margin
59.8%
Operating Margin
41.4%
-304.8%
Net Margin
37.6%
-304.2%
Revenue YoY
20.6%
681.7%
Net Profit YoY
73.5%
39.6%
EPS (diluted)
$0.94
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OBT
OBT
RXRX
RXRX
Q4 25
$33.0M
$35.5M
Q3 25
$33.7M
$5.2M
Q2 25
$32.5M
$19.2M
Q1 25
$28.0M
$14.7M
Q4 24
$27.4M
$4.5M
Q3 24
$27.1M
$26.1M
Q2 24
$27.9M
$14.4M
Q1 24
$25.3M
$13.8M
Net Profit
OBT
OBT
RXRX
RXRX
Q4 25
$12.4M
$-108.1M
Q3 25
$10.0M
$-162.3M
Q2 25
$10.5M
$-171.9M
Q1 25
$8.7M
$-202.5M
Q4 24
$7.2M
$-178.9M
Q3 24
$3.2M
$-95.8M
Q2 24
$8.2M
$-97.5M
Q1 24
$9.3M
$-91.4M
Gross Margin
OBT
OBT
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
OBT
OBT
RXRX
RXRX
Q4 25
41.4%
-304.8%
Q3 25
38.6%
-3327.6%
Q2 25
41.9%
-916.8%
Q1 25
40.3%
-1297.9%
Q4 24
32.8%
-4042.4%
Q3 24
14.8%
-377.1%
Q2 24
36.6%
-697.4%
Q1 24
45.9%
-698.4%
Net Margin
OBT
OBT
RXRX
RXRX
Q4 25
37.6%
-304.2%
Q3 25
29.7%
-3135.3%
Q2 25
32.2%
-894.2%
Q1 25
31.1%
-1373.3%
Q4 24
26.2%
-3935.5%
Q3 24
11.8%
-367.5%
Q2 24
29.4%
-676.6%
Q1 24
36.7%
-662.4%
EPS (diluted)
OBT
OBT
RXRX
RXRX
Q4 25
$0.94
$-0.17
Q3 25
$0.75
$-0.36
Q2 25
$0.87
$-0.41
Q1 25
$0.77
$-0.50
Q4 24
$0.64
$-0.56
Q3 24
$0.28
$-0.34
Q2 24
$0.73
$-0.40
Q1 24
$0.82
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OBT
OBT
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$284.4M
$1.1B
Total Assets
$2.7B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OBT
OBT
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
OBT
OBT
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
OBT
OBT
RXRX
RXRX
Q4 25
$284.4M
$1.1B
Q3 25
$270.1M
$1.0B
Q2 25
$252.6M
$919.1M
Q1 25
$201.3M
$933.9M
Q4 24
$185.5M
$1.0B
Q3 24
$193.1M
$524.6M
Q2 24
$177.5M
$584.4M
Q1 24
$168.7M
$401.2M
Total Assets
OBT
OBT
RXRX
RXRX
Q4 25
$2.7B
$1.5B
Q3 25
$2.6B
$1.4B
Q2 25
$2.6B
$1.3B
Q1 25
$2.6B
$1.3B
Q4 24
$2.5B
$1.4B
Q3 24
$2.5B
$726.5M
Q2 24
$2.5B
$775.9M
Q1 24
$2.5B
$557.8M
Debt / Equity
OBT
OBT
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OBT
OBT
RXRX
RXRX
Operating Cash FlowLast quarter
$43.8M
$-46.1M
Free Cash FlowOCF − Capex
$41.3M
$-47.3M
FCF MarginFCF / Revenue
125.1%
-133.1%
Capex IntensityCapex / Revenue
7.6%
3.5%
Cash ConversionOCF / Net Profit
3.53×
TTM Free Cash FlowTrailing 4 quarters
$69.6M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OBT
OBT
RXRX
RXRX
Q4 25
$43.8M
$-46.1M
Q3 25
$30.2M
$-117.4M
Q2 25
$-5.0M
$-76.4M
Q1 25
$4.8M
$-132.0M
Q4 24
$34.6M
$-115.4M
Q3 24
$10.2M
$-59.2M
Q2 24
$9.3M
$-82.2M
Q1 24
$2.3M
$-102.3M
Free Cash Flow
OBT
OBT
RXRX
RXRX
Q4 25
$41.3M
$-47.3M
Q3 25
$29.6M
$-117.6M
Q2 25
$-5.7M
$-79.6M
Q1 25
$4.3M
$-133.8M
Q4 24
$32.9M
$-116.7M
Q3 24
$10.0M
$-63.8M
Q2 24
$9.2M
$-83.4M
Q1 24
$2.0M
$-109.0M
FCF Margin
OBT
OBT
RXRX
RXRX
Q4 25
125.1%
-133.1%
Q3 25
87.8%
-2272.5%
Q2 25
-17.5%
-413.9%
Q1 25
15.5%
-907.4%
Q4 24
120.0%
-2567.7%
Q3 24
36.7%
-244.6%
Q2 24
32.8%
-578.5%
Q1 24
7.9%
-789.9%
Capex Intensity
OBT
OBT
RXRX
RXRX
Q4 25
7.6%
3.5%
Q3 25
1.8%
4.7%
Q2 25
2.3%
16.4%
Q1 25
1.8%
12.4%
Q4 24
6.3%
28.6%
Q3 24
1.1%
17.5%
Q2 24
0.4%
8.2%
Q1 24
1.0%
48.2%
Cash Conversion
OBT
OBT
RXRX
RXRX
Q4 25
3.53×
Q3 25
3.01×
Q2 25
-0.47×
Q1 25
0.56×
Q4 24
4.83×
Q3 24
3.19×
Q2 24
1.13×
Q1 24
0.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons